As of 2025-04-23, the EV/EBITDA ratio of Regenxbio Inc (RGNX) is -1.29. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RGNX's latest enterprise value is 276.77 mil USD. RGNX's TTM EBITDA according to its financial statements is -215.03 mil USD. Dividing these 2 quantities gives us the above RGNX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.8x - 12.4x | 11.1x |
| Forward P/E multiples | 19.5x - 41.2x | 30.4x |
| Fair Price | (82.51) - (52.05) | (87.77) |
| Upside | -1337.1% - -880.4% | -1415.9% |
| Date | EV/EBITDA |
| 2025-04-21 | -1.29 |
| 2025-04-17 | -1.12 |
| 2025-04-16 | -1.17 |
| 2025-04-15 | -1.26 |
| 2025-04-14 | -1.21 |
| 2025-04-11 | -1.11 |
| 2025-04-10 | -0.99 |
| 2025-04-09 | -1.11 |
| 2025-04-08 | -0.97 |
| 2025-04-07 | -1.11 |
| 2025-04-04 | -1.20 |
| 2025-04-03 | -1.29 |
| 2025-04-02 | -1.38 |
| 2025-04-01 | -1.31 |
| 2025-03-31 | -1.40 |
| 2025-03-28 | -1.56 |
| 2025-03-27 | -1.58 |
| 2025-03-26 | -1.64 |
| 2025-03-25 | -1.65 |
| 2025-03-24 | -1.76 |
| 2025-03-21 | -1.65 |
| 2025-03-20 | -1.68 |
| 2025-03-19 | -1.71 |
| 2025-03-18 | -1.55 |
| 2025-03-17 | -1.36 |
| 2025-03-14 | -1.30 |
| 2025-03-13 | -1.26 |
| 2025-03-12 | -1.29 |
| 2025-03-11 | -1.16 |
| 2025-03-10 | -1.13 |
| 2025-03-07 | -1.21 |
| 2025-03-06 | -1.24 |
| 2025-03-05 | -1.19 |
| 2025-03-04 | -1.11 |
| 2025-03-03 | -1.11 |
| 2025-02-28 | -1.26 |
| 2025-02-27 | -1.27 |
| 2025-02-26 | -1.29 |
| 2025-02-25 | -1.30 |
| 2025-02-24 | -1.35 |
| 2025-02-21 | -1.43 |
| 2025-02-20 | -1.45 |
| 2025-02-19 | -1.47 |
| 2025-02-18 | -1.50 |
| 2025-02-14 | -1.43 |
| 2025-02-13 | -1.44 |
| 2025-02-12 | -1.41 |
| 2025-02-11 | -1.44 |
| 2025-02-10 | -1.57 |
| 2025-02-07 | -1.65 |